MCM
NGNE icon

Moore Capital Management’s Neurogene NGNE Stock Holding History

Moore Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,000
Closed -$240K – 576
2020
Q3 		$240K Buy
+1,000
New +$242K ﹤0.01% 341

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moore Capital Management's NGNE Position: Q4 2020 in Review

Moore Capital Management sold out of Neurogene (NGNE) in Q4 2020, closing a stake of 1,000 shares — an estimated $240K sold.

Moore Capital Management first reported a position in NGNE in Q3 2020 and held it in 1 quarter. The position peaked at $240K in Q3 2020. 84 funds tracked by Wall St. Rank hold NGNE as of Q4 2020.

  • Moore Capital Management reported no remaining Neurogene position as of Q4 2020 after selling out during the quarter.
  • Moore Capital Management sold 1,000 Neurogene shares in Q4 2020, an estimated $240K.
  • Moore Capital Management first reported a position in Neurogene in Q3 2020 and held it in 1 quarter.
  • Moore Capital Management's Neurogene position peaked at $240K in Q3 2020.
  • 84 funds tracked by Wall St. Rank held Neurogene as of Q4 2020.

Based on Moore Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.